Episode 6: Stephanie Oestreich, Myeloma Investment Fund

On Episode 6 of the Aayaam 360 Podcast, I speak with Stephanie Oestreich, Managing Director of Myeloma Investment Fund (MIF). MIF is a six-year-old fund, focused on the blood cancer of Multiple Myeloma. This investment fund is part of Multiple Myeloma Research Foundation, a 26-year-old patient foundation that provides information to patients and helps run Multiple Myeloma clinical trials. So far, MIF has made 20 investments, with 3 exits.

One of MIF’s latest investments is in Coding Bio, an Oxford, UK based biotech company that is engineering modular immunotherapies for cancer by combining high-throughput cellular screening with machine learning. Screening millions of protein candidates in living cells to identify the best designs for inducing an immune response can lead to faster development of best-in-class immunotherapies.

Check out the full episode!